← All trials
NCT04601441
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 6, 2020
- Primary completion
- Mar 31, 2025
- Completion date
- Mar 31, 2025
- First posted
- Oct 23, 2020
- Last posted
- Dec 8, 2020
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Kindai UniversityLead sponsor
- Janssen Pharmaceutica NVCollaborator
- Kindai UniversityReponsible party - principal investigator
- Kindai UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.